On December 5th, GUSHENGTANG (02273) spent 5.2936 million Hong Kong dollars to repurchase 186,000 shares.
Kyu Sang Tong (02273) announced that the company repurchased 186,000 shares on December 5, 2025, at a cost of 5.2936 million Hong Kong dollars, with a repurchase price of 28.46 Hong Kong dollars per share.
GUSHENGTANG (02273) announced that the company will spend 5.2936 million Hong Kong dollars to repurchase 186,000 shares on December 5, 2025, at a repurchase price of 28.46 Hong Kong dollars per share.
Related Articles
HAOHAI BIOTEC (06826) spent 837,000 Hong Kong dollars to repurchase 30,500 shares on December 5th.
The controlling shareholder of KONTA CHINA (01312) remains unchanged. Shanxi Construction Investment holds 52.44% of the shares and Shanxi Communications holds 90% of the shares have been transferred to the Shanxi Provincial State-owned Assets Supervision and Administration Commission.
CSPC PHARMA (01093): GLP-1/GIP receptor biased agonist dual peptide injection approved for clinical trials in the United States.
HAOHAI BIOTEC (06826) spent 837,000 Hong Kong dollars to repurchase 30,500 shares on December 5th.
The controlling shareholder of KONTA CHINA (01312) remains unchanged. Shanxi Construction Investment holds 52.44% of the shares and Shanxi Communications holds 90% of the shares have been transferred to the Shanxi Provincial State-owned Assets Supervision and Administration Commission.
CSPC PHARMA (01093): GLP-1/GIP receptor biased agonist dual peptide injection approved for clinical trials in the United States.
